A Phase 1b/2, First in Human, Dose Escalation and Expansion Study of XMT 1536 In Patients with Solid Tumors Likely to Express NaPi2b
For more information about the trial above please contact the study team:
Principal Investigator, Brian Orr, at email@example.com.
Study Coordinator, Linda Washington, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina